After two rounds of mixed data, Eli Lilly impresses analysts with new Covid-19 antibody results. And execs want an EUA now
Eli Lilly has more data from their Covid-19 neutralizing antibodies — data, they say, should warrant an FDA OK.
The Big Pharma said Wednesday that a cocktail of two monoclonal antibodies looked safe and reduced viral load in Covid-19 patients. It also alleviated symptoms and reduced ER visits and hospitalization rate compared to placebo, appearing overall to provide better results than a single Lilly antibody showed in September and to compare favorably with the Regeneron antibody cocktail that President Trump received last week.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.